Septerna, Inc. (SEPN) Spending and interest coverage
- R&D / revenue · 12 months: Value 122.16%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 16.46%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 122.16% | Research and development expense / revenue. Period ending 2026-06-30. $120.79M ÷ $98.88M × 100 ≈ 122.16% |
| Stock-based compensation / revenue · 12 months | 16.46% | Share-based compensation / revenue. Period ending 2026-06-30. $16.28M ÷ $98.88M × 100 ≈ 16.46% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 120.79M USD | Research and Development Expense |
| Revenue | 98.88M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 16.28M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -43.55M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $120.79M | $98.88M | $16.28M | $-43.55M | (m) | 122.16% | 16.46% | (m) | (m) |
| 2026-03-31 | $107.85M | $72.25M | $13.01M | $-55.69M | (m) | 149.26% | 18.00% | (m) | (m) |
| 2025-12-31 | $97.58M | $45.95M | $8.48M | $-68.30M | (m) | 212.37% | 18.45% | (m) | (m) |
| 2025-09-30 | $85.04M | $22.05M | $7.08M | $-76.99M | (m) | 385.76% | 32.13% | (m) | (m) |
| 2025-06-30 | $78.61M | $726.00K | $5.24M | $-102.16M | (m) | 10827.55% | 721.07% | (m) | (m) |
| 2025-03-31 | $71.45M | $977.00K | $4.06M | $-91.24M | (m) | 7313.72% | 415.25% | (m) | (m) |
| 2024-12-31 | $65.34M | $1.07M | $3.15M | $-80.82M | (m) | 6077.86% | 293.21% | (m) | (m) |
| 2024-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $35.98M | $151.00K | $1.62M | $2.08M | (m) | 23827.15% | 1072.85% | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |